Do you want to read an article? Please log in or register.
Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
A Real-World Longitudinal Case-Study Implementing Digital Screening and Treatment for Distress in Inflammatory Bowel Disease: The COMPASS-IBD Patient Journey
Inflamm Bowel Dis
Jones ASK, Seaton N, Harding S, Duff A, Hudson J, Wroe A, Norton S, Singh H, Onih J, Moss-Morris R
doi: 10.1093/ibd/izaf259
Inflammatory Bowel Disease
Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services
J Crohns Colitis
Hawthorne AB, Christiansen P, Arnott I, Cummings F, Dobson L, Kent A, Limdi JK, Mulligan RJ, Parkes GC, Rees F, Selinger CP, Turner J, Woo N, Younge L, Contributors to the IBD UK Task & Finish group, IBD Service Survey Collaborators, Lamb CA
doi: 10.1093/ecco-jcc/jjag005
COMMENTED
Inflammatory Bowel DiseaseFurther Publications
A Prospective Interventional Study to Evaluate the Effect of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease: The Altitude Inflammatory Bowel Disease Study
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Am J Gastroenterol
Vavricka SR, Zeitz J, Madanchi M, Ruiz PA, Biedermann L, Morsy Y, Yilmaz B, Scharl M, Scharl S, Gassmann M, Lutz TA, Kunz A, Bron D, Misselwitz B, MacPherson AJ, Rogler G, Greuter T
doi: 10.14309/ajg.0000000000003888
Inflammatory Bowel Disease
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab
Inflamm Bowel Dis
Lee J, Porth R, Saraga A, Gade A, Deyhim T, Soliman M, Moini SH, Zullow S, Rabinowitz L, Grossberg L, Cheifetz AS, Papamichael K
doi: 10.1093/ibd/izag139
Inflammatory Bowel Disease
Meta-analysis: safety and efficacy of ustekinumab in pediatric inflammatory bowel disease patients with anti-TNF failure
BMC Gastroenterol
Heng Z, Zhan L, Zhang Y, Xu K, Song M, Zhao K, Jahan MS, Akter MF, Lu P, Ji Y, Liu Y
doi: 10.1186/s12876-026-05078-9
Inflammatory Bowel Disease
Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylates
Clin Gastroenterol Hepatol
Bertrand A, Amiot A, Martin A, Carbonnel F, Meyer A
doi: 10.1016/j.cgh.2026.04.015
Inflammatory Bowel Disease
Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)
Inflamm Bowel Dis
Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, Huang TY, Yen HH, Tsai TJ, Lin CP, Chang CH, Tai CM, Tai WC, Yao CC, Chen CC, Pan YB, Le PH
doi: 10.1093/ibd/izag150
Inflammatory Bowel Disease
Third N-ECCO Consensus Statements on the Nursing Roles in Caring for Patients with Inflammatory Bowel Disease
J Crohns Colitis
Jäghult S, Adamina M, Farrell D, Bager P, Czuber-Dochan W, Kemp K, Boontje N, D'Amico F, Dewitte G, Haj O, Hartmann P, Lightowler D, Locher R, Maia C, Murciano Gonzalo F, Napolitano D, Özgürsoy Uran BN, Lesnovska KP, Radford S, Rivera Sequeiros A, Sarbagili-Shabat C, Tiitta Inkeri Toivonen T, Walsh C, Zaetta D, Radice S
doi: 10.1093/ecco-jcc/jjag054
Inflammatory Bowel Disease
Clinical Research: Disparities in Outcomes for Patients With Inflammatory Bowel Disease at a Private vs Public Hospital in New York City
Inflamm Bowel Dis
Klein S, Sivasailam B, Alizadeh M, Malter L, Axelrad JE
doi: 10.1093/ibd/izaf174